COURAGENCT06299098
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 16 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Trial completed
- Site details revised at 1 of 60 sites
- Minor Primary completion pushed from May 6, 2026 to Jun 16, 2026
- Study completion date: Oct 30, 2026 to Oct 21, 2026
- Minor Primary completion date changed from estimate of May 18, 2026 to May 6, 2026v14
- Study Status, Referencesv13
- Minor Primary completion date: May 13, 2026 to May 18, 2026
- Study completion date: Nov 4, 2026 to Oct 30, 2026
- Secondary endpoints revised (21)
Show 10 earlier versionsHide 10 earlier versions
Notable Primary endpoints: 4 to 8v11 Show 7 more changesShow less
- Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 999 to confirmed 1005
- Study sites: 61 to 60
- Primary completion date: May 27, 2026 to May 13, 2026
- Study completion date: Nov 20, 2026 to Nov 4, 2026
- Secondary endpoints: 31 to 21
- Study title expanded, about 3 words
Notable Trial status: Active, Not Recruiting to Recruitingv10 Show 4 more changesShow less
- Study sites: 59 to 61
- Primary completion date: Feb 16, 2026 to May 27, 2026
- Study completion date: Aug 17, 2026 to Nov 20, 2026
- Secondary endpoints: 32 to 31
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 59 of 59 sites
Notable Enrollment target: 624 to 999v8 Show 8 more changesShow less
- Eligibility criteria expanded, about 11 words
- Study sites: 51 to 59
- Primary completion date: Jun 24, 2026 to Feb 16, 2026
- Study completion date: Jun 24, 2026 to Aug 17, 2026
- Interventions: Garetosmab (Drug), Matching Placebo-Garetosmab (Drug), Matching Placebo-Part A (Drug), Matching Placebo-Trevogrumab (Drug), Semaglutide… to Garetosmab (Drug), Matching Placebo-Garetosmab (Drug), Matching Placebo-Part A (Drug), Matching Placebo-Trevogrumab (Drug), Semaglutide…
- Secondary endpoints: 31 to 32
- Study arms: 10 to 13
- Study description expanded, about 3 words
- Minor Study sites: 27 to 51v7
- Minor Study sites: 19 to 27v6
- Minor Study sites: 11 to 19v5
- Notable Trial status: Active, Not Recruiting to Recruiting
- Study sites: 3 to 11
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 3 of 3 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 16 words
- Study sites: 0 to 3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (17)
Show 12 moreShow less
Arms and interventions
Part A Randomized 1:1
Part A Randomized 1:1
Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1
Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Part C Sema and SC placebo Randomized 1:2:2
Part C Sema and SC low dose trevo Randomized 1:2:2
Part C Sema and SC moderate dose trevo Randomized 1:2:2
Drugs: Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab
Sites
60 sites in 2 countries
United States 58, Puerto Rico 2